908 Devices Inc (MASS) - Net Assets
Based on the latest financial reports, 908 Devices Inc (MASS) has net assets worth $143.70 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($190.07 Million) and total liabilities ($46.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 908 Devices Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $143.70 Million |
| % of Total Assets | 75.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.04% |
| 10-Year Change | N/A |
| Growth Volatility | 30.73 |
908 Devices Inc - Net Assets Trend (2018–2025)
This chart illustrates how 908 Devices Inc's net assets have evolved over time, based on quarterly financial data. Also explore 908 Devices Inc (MASS) total assets for the complete picture of this company's asset base.
Annual Net Assets for 908 Devices Inc (2018–2025)
The table below shows the annual net assets of 908 Devices Inc from 2018 to 2025. For live valuation and market cap data, see 908 Devices Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $143.70 Million | +25.40% |
| 2024-12-31 | $114.59 Million | -30.76% |
| 2023-12-31 | $165.49 Million | -13.17% |
| 2022-12-31 | $190.60 Million | -11.19% |
| 2021-12-31 | $214.60 Million | +54.35% |
| 2020-12-31 | $139.04 Million | +320.11% |
| 2019-12-31 | $-63.17 Million | -25.89% |
| 2018-12-31 | $-50.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 908 Devices Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17104000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $36.00K | 0.03% |
| Other Comprehensive Income | $54.00K | 0.04% |
| Other Components | $366.93 Million | 255.34% |
| Total Equity | $143.70 Million | 100.00% |
908 Devices Inc Competitors by Market Cap
The table below lists competitors of 908 Devices Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alvopetro Energy
V:ALV
|
$230.37 Million |
|
Bicycle Therapeutics plc
F:50BA
|
$230.38 Million |
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
$230.47 Million |
|
Starz Entertainment LLC
NASDAQ:STRZ
|
$230.69 Million |
|
Salmon Evolution Holding AS
OL:SALME
|
$230.25 Million |
|
Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS
IS:SONME
|
$230.21 Million |
|
Dynamix Corporation Unit
NASDAQ:DYNXU
|
$230.20 Million |
|
Artius II Acquisition Inc. Class A Ordinary Shares
NASDAQ:AACB
|
$230.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 908 Devices Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 114,592,000 to 143,699,000, a change of 29,107,000 (25.4%).
- Net income of 19,489,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,092,000.
- Other factors increased equity by 10,710,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $19.49 Million | +13.56% |
| Other Comprehensive Income | $-1.09 Million | -0.76% |
| Other Changes | $10.71 Million | +7.45% |
| Total Change | $- | 25.40% |
Book Value vs Market Value Analysis
This analysis compares 908 Devices Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-6.18 | $6.81 | x |
| 2019-12-31 | $-8.39 | $6.81 | x |
| 2020-12-31 | $25.35 | $6.81 | x |
| 2021-12-31 | $7.68 | $6.81 | x |
| 2022-12-31 | $6.05 | $6.81 | x |
| 2023-12-31 | $5.13 | $6.81 | x |
| 2024-12-31 | $3.36 | $6.81 | x |
| 2025-12-31 | $3.69 | $6.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 908 Devices Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.56%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.68%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.32x
- Recent ROE (13.56%) is above the historical average (-13.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -34.17% | 0.79x | 0.00x | $-2.52 Million |
| 2019 | 0.00% | -74.41% | 0.48x | 0.00x | $-7.06 Million |
| 2020 | -9.22% | -47.66% | 0.15x | 1.29x | $-26.72 Million |
| 2021 | -10.33% | -52.53% | 0.16x | 1.22x | $-43.63 Million |
| 2022 | -16.65% | -67.75% | 0.19x | 1.27x | $-50.80 Million |
| 2023 | -21.99% | -72.47% | 0.25x | 1.23x | $-52.95 Million |
| 2024 | -63.01% | -121.09% | 0.37x | 1.39x | $-83.67 Million |
| 2025 | 13.56% | 34.68% | 0.30x | 1.32x | $5.12 Million |
Industry Comparison
This section compares 908 Devices Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 908 Devices Inc (MASS) | $143.70 Million | 0.00% | 0.32x | $230.37 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About 908 Devices Inc
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of… Read more